Before today's market open, the Ewing, NJ-based specialty pharmaceutical company posted a net loss of 4 cents per share, narrower than the loss of 3 cents per share that analysts had expected.
Revenue rose by 40% to $11.8 million year-over-year, but fell short of analysts' estimates of $12.5 million.
"We continued growing the product sales portion of total revenue, recording our eighth consecutive quarterly increase," CEO Robert F. Apple said in a statement.
"The fourth quarter also brought continued progress from our pipeline with the approval of our abbreviated new drug application for Sumatriptan Injection USP for the acute treatment of migraine and cluster headache," he added.
Antares Pharma focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D on the stock.
This is driven by several weaknesses, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ATRSATRS data by YCharts